Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context

被引:9
|
作者
Brusco, Natasha K. [1 ,2 ]
Bury, Susan [3 ,4 ]
Chua, Kyra Y. L. [3 ]
Vogrin, Sara [5 ]
Holmes, Natasha E. [3 ,6 ,7 ,8 ]
Trubiano, Jason A. [3 ,9 ,10 ,11 ]
机构
[1] Monash Univ, Alpha Crucis Grp, Hlth Econ, Clayton, Vic, Australia
[2] Monash Univ, Rehabil Ageing & Independent Living RAIL Res Ctr, Clayton, Vic, Australia
[3] Austin Hlth, Dept Infect Dis, 145 Studley Rd, Heidelberg, Vic 3084, Australia
[4] Austin Hlth, Dept Pharm, Heidelberg, Vic, Australia
[5] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia
[6] Univ Melbourne, Dept Med & Radiol, Melbourne, Vic, Australia
[7] Austin Hlth, Data Analyt Res & Evaluat DARE Ctr, Heidelberg, Vic, Australia
[8] Univ Melbourne, Melbourne, Vic, Australia
[9] Univ Melbourne, Austin Hlth, Dept Med, Melbourne, Vic, Australia
[10] Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
[11] Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia
关键词
Antibiotics; Delabeling; Health Economics; Health Service Research; COST-EFFECTIVENESS; HEALTH;
D O I
10.1111/imj.15532
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Internationally, clinical and economic advantages of low-risk penicillin delabelling have been explored, supporting changes to healthcare delivery systems where penicillin delabelling is embedded into inpatient usual care. Aims To determine if economic advantages of low-risk inpatient penicillin delabelling, described in the international literature, are realised in the Australian context. Methods This explorative economic evaluation had prospective patient data collection between January and August 2019, across two Australian health services. Part 1: determine the cost per effectively delabelled patient for Penicillin Allergy Delabeling Program inpatients (PADP cohort) compared with Outpatient Antibiotic Allergy Testing Service outpatients (OAATS cohort). Part 2: a cost analysis to compare hospital costs for inpatients with low-risk penicillin allergy who did (PADP cohort) and did not (usual care cohort) undergo PADP delabelling. Results Part 1: the PADP (n = 350) and OAATS (n = 27 patients, n = 36 individual visits) cohorts were comparable. In PADP, costs/proportion delabelled was $20.10/0.98, equating to $20.51 per effectively delabelled patient; in OAATS, it was $181.24/0.50, equating to $362. Compared with OAATS, PADP was associated with savings of $341.97 per effectively delabelled patient, indicating the outpatient testing was the dominated strategy, being more costly and less effective. Part 2: the PADP (n = 218) and usual care (n = 32) cohorts were comparable. Significantly favouring the delabelled PADP cohort, the mean difference per patient was -4.41 days (95% confidence interval: -7.64, -1.18) and -$9467.72 (95% confidence interval: -$15 419.98, -$3515.46). Conclusions Consistent with international literature, delabelling low-risk penicillin allergies in the inpatient setting had economic advantages in the Australian context. Fully powered economic evaluations are urgently required to consolidate these findings.
引用
收藏
页码:74 / 83
页数:10
相关论文
共 50 条
  • [31] Impact of an inpatient nurse-initiated penicillin allergy delabeling questionnaire
    Bediako, Hilary
    Dutcher, Lauren
    Rao, Aditi
    Sigafus, Kristen
    Harker, Christina
    Hamilton, Keith W.
    Fadugba, Olajumoke
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2022, 2 (01):
  • [32] History of penicillin allergy and referral for skin testing: evaluation of a pediatric penicillin allergy testing program
    Langley, JM
    Halperin, SA
    Bortolussi, R
    CLINICAL AND INVESTIGATIVE MEDICINE, 2002, 25 (05): : 181 - 184
  • [33] Caregiver perceptions on pediatric penicillin allergy delabeling in a primary care setting
    Lee, Hannah J.
    Hart, Margaret
    Chow, Timothy G.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (03) : 349 - 351
  • [34] A Quality Improvement Initiative for Engaging Physicians in Inpatient Penicillin Allergy DeLabeling
    Licata, Christine
    Dimitriades, Victoria
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB166 - AB166
  • [35] Another Step Forward in the Optimization of Penicillin Allergy Delabeling Strategies in Children
    Schroer, Brian
    Macy, Eric
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (11): : 4067 - 4068
  • [36] Children with reported penicillin allergy Public health impact and safety of delabeling
    Vyles, David
    Antoon, James W.
    Norton, Allison
    Stone, Cosby A., Jr.
    Trubiano, Jason
    Radowicz, Alexandra
    Phillips, Elizabeth J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 124 (06) : 558 - 565
  • [37] Durability of penicillin allergy delabeling and post-testing penicillin utilization in adults with immune compromise
    Rose, Morgan T.
    Mitri, Elise A.
    Vogrin, Sara
    Holmes, Natasha E.
    Chua, Kyra Y. L.
    Slavin, Monica A.
    Trubiano, Jason A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (07): : 1928 - 1930.e1
  • [38] Follow-up of penicillin allergy labels 1 year after successful penicillin delabeling
    Pinto, Trisha
    Li, Jamma
    Boyle, Therese
    Zaragoza, Reina
    Fernando, Suran L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 130 (01) : 80 - +
  • [39] Addressing the Challenges of Penicillin Allergy Delabeling With Electronic Health Records and Mobile Applications
    Powell, Neil
    Elkhalifa, Shuayb
    Guyer, Autumn
    Garcez, Tomaz
    Sandoe, Jonathan
    Zhou, Li
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (02): : 414 - 421
  • [40] PENICILLIN ALLERGY DELABELING PREVALENCE AND IMPACT OF HEALTHCARE UTILIZATION IN A PRIMARY CARE COHORT
    Mann, J.
    King, A.
    Jiang, B.
    Asupoto, O.
    Bartels, S.
    Zhang, Y.
    Wurcel, A.
    Blumenthal, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S13 - S13